Aldeyra Therapeutics Statistics
Total Valuation
ALDX has a market cap or net worth of $312.56 million. The enterprise value is $247.86 million.
Important Dates
The next estimated earnings date is Friday, November 8, 2024, before market open.
| Earnings Date | Nov 8, 2024 |
| Ex-Dividend Date | n/a |
Share Statistics
ALDX has 59.42 million shares outstanding. The number of shares has increased by 1.03% in one year.
| Shares Outstanding | 59.42M |
| Shares Change (YoY) | +1.03% |
| Shares Change (QoQ) | n/a |
| Owned by Insiders (%) | 2.59% |
| Owned by Institutions (%) | 35.40% |
| Float | 43.13M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | n/a |
| Forward PS | n/a |
| PB Ratio | 3.18 |
| P/FCF Ratio | n/a |
| PEG Ratio | n/a |
Financial Ratio HistoryEnterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 4.55, with a Debt / Equity ratio of 0.16.
| Current Ratio | 4.55 |
| Quick Ratio | 2.91 |
| Debt / Equity | 0.16 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | -21.22 |
Financial Efficiency
Return on equity (ROE) is -33.19% and return on invested capital (ROIC) is -20.70%.
| Return on Equity (ROE) | -33.19% |
| Return on Assets (ROA) | -19.11% |
| Return on Capital (ROIC) | -20.70% |
| Revenue Per Employee | n/a |
| Profits Per Employee | -$3.79M |
| Employee Count | 10 |
| Asset Turnover | n/a |
| Inventory Turnover | n/a |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has increased by +241.56% in the last 52 weeks. The beta is 1.43, so ALDX's price volatility has been higher than the market average.
| Beta (5Y) | 1.43 |
| 52-Week Price Change | +241.56% |
| 50-Day Moving Average | 5.59 |
| 200-Day Moving Average | 4.20 |
| Relative Strength Index (RSI) | 44.40 |
| Average Volume (20 Days) | 383,854 |
Short Selling Information
The latest short interest is 3.40 million, so 5.73% of the outstanding shares have been sold short.
| Short Interest | 3.40M |
| Short Previous Month | 3.00M |
| Short % of Shares Out | 5.73% |
| Short % of Float | 7.89% |
| Short Ratio (days to cover) | 7.52 |
Income Statement
| Revenue | n/a |
| Gross Profit | n/a |
| Operating Income | -43.05M |
| Pretax Income | -37.87M |
| Net Income | -37.87M |
| EBITDA | -42.80M |
| EBIT | -43.05M |
| Earnings Per Share (EPS) | -$0.64 |
Full Income StatementBalance Sheet
The company has $80.33 million in cash and $15.64 million in debt, giving a net cash position of $64.70 million or $1.09 per share.
| Cash & Cash Equivalents | 80.33M |
| Total Debt | 15.64M |
| Net Cash | 64.70M |
| Net Cash Per Share | $1.09 |
| Equity (Book Value) | 98.31M |
| Book Value Per Share | 1.65 |
| Working Capital | 98.05M |
Full Balance SheetCash Flow
| Operating Cash Flow | -30.72M |
| Capital Expenditures | n/a |
| Free Cash Flow | -30.72M |
| FCF Per Share | -$0.52 |
Full Cash Flow StatementMargins
| Gross Margin | n/a |
| Operating Margin | n/a |
| Pretax Margin | n/a |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |